Merck is in talks to buy cancer drug developer Revolution Medicines in a deal that may be worth $28 billion to $32 billion ...

Focusing on 2026 as a starting point, PwC has laid out several “strategic imperatives” pharma companies ought to pursue this ...

A worldwide leader in injectable drug administration will be the newest company to set up shop in Greenfield, and anticipates ...

Next-generation biologics, such as bispecifics, fusion proteins, and multi-specifics, have multiple functionalities that ...

As they prepare for the J.P. Morgan Healthcare Conference next week, biotech leaders and analysts say companies are better ...

Our first biotech bi-weekly of 2026 is here with recent innovations in genomic drug discovery, organoid development and ADC ...

F rom blockbuster drugs that garner media attention to smaller innovations that help millions maintain health, the biotech and pharmaceutical industries have an impact on everyone’s life. Meanwhile, ...

T he biotech and pharmaceutical sectors stand at the brink of innovation and strategic transformation. Market momentum continues to build, with the global biotechnology market valued at around $2 ...

Sun Pharma's Managing Director, Kirti Ganorkar, predicts that new age medicines for obesity and diabetes will drive the ...

Biotech's 2025 rebound sets the stage for Denali Therapeutics and two peers, with key FDA decisions and pipeline catalysts ...

Pharmaceutical products are now at the top of patent filings in Morocco, showing a strong push in research, innovation, and business creation across several sectors, according to figures released by ...

A Relative Strength Rating upgrade for Takeda Pharmaceutical ADR shows improving technical performance. Will it continue?